These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29468652)

  • 1. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
    Castillo JJ; Gustine JN; Meid K; Dubeau TE; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
    Br J Haematol; 2018 Apr; 181(1):77-85. PubMed ID: 29468652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia.
    Abeykoon JP; Zanwar S; Ansell SM; Muchtar E; He R; Greipp PT; King RL; Ailawadhi S; Paludo J; Larsen JT; Habermann TM; Inwards D; Go RS; Thanarajasingam G; Buadi F; Dispenzieri A; Thompson CA; Witzig TE; Lacy M; Gonsalves W; Nowakowski GS; Dingli D; Rajkumar SV; Kyle RA; Sher T; Roy V; Rosenthal A; Chanan-Khan AA; Reeder C; Gertz MA; Kumar S; Kapoor P
    Am J Hematol; 2021 Aug; 96(8):945-953. PubMed ID: 33909933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
    Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
    Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
    Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
    Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.
    Olszewski AJ; Chen C; Gutman R; Treon SP; Castillo JJ
    Br J Haematol; 2017 Oct; 179(1):106-115. PubMed ID: 28677830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
    Laribi K; Poulain S; Willems L; Merabet F; Herbaux C; Roos-Weil D; Laribi de Materre I; Roussel X; Nudel M; Tricot S; Dupuis J; Le Calloch R; Bareau B; Leblond V
    Br J Haematol; 2024 Jun; 204(6):2233-2236. PubMed ID: 38504454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
    Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
    J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of Waldenström´s macroglobulinaemia in the year 2014].
    Adam Z; Krejčí M; Pour L; Ševčíková E
    Vnitr Lek; 2014 Feb; 60(2):139-57. PubMed ID: 24754419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.
    Castillo JJ; Meid K; Gustine JN; Dubeau T; Severns P; Hunter ZR; Yang G; Xu L; Treon SP
    Clin Cancer Res; 2018 Jul; 24(14):3247-3252. PubMed ID: 29661775
    [No Abstract]   [Full Text] [Related]  

  • 11. Circulating low CD4
    Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
    Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.
    Gavriatopoulou M; García-Sanz R; Kastritis E; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Sonneveld P; Dimopoulos MA
    Blood; 2017 Jan; 129(4):456-459. PubMed ID: 27872060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.
    Herth I; Hensel M; Rieger M; Horstmann K; Hiddemann W; Dreyling M; Koniczek S; Witzens-Harig M; Ho AD
    Leuk Lymphoma; 2015 Jan; 56(1):97-102. PubMed ID: 24724778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
    Castillo JJ; Gustine JN; Keezer A; Meid K; Flynn CA; Dubeau TE; Chan G; Chen J; Demos MG; Guerrera ML; Jimenez C; Kofides A; Liu X; Munshi M; Tsakmaklis N; Patterson CJ; Xu L; Yang G; Hunter ZR; Treon SP
    Am J Hematol; 2020 Apr; 95(4):372-378. PubMed ID: 31868242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
    Treon SP; Yang G; Hanzis C; Ioakimidis L; Verselis SJ; Fox EA; Xu L; Hunter ZR; Tseng H; Manning RJ; Patterson CJ; Sheehy P; Turnbull B
    Br J Haematol; 2011 Jul; 154(2):223-8. PubMed ID: 21564078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
    Ghobrial IM; Xie W; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Poon T; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
    Am J Hematol; 2010 Sep; 85(9):670-4. PubMed ID: 20652865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.
    Tedeschi A; Picardi P; Ferrero S; Benevolo G; Margiotta Casaluci G; Varettoni M; Baratè C; Motta M; Gini G; Goldaniga MC; Visco C; Zaja F; Belsito Petrizi V; Ravelli E; Gentile M; Urbano MA; Franceschetti S; Ghione P; Orsucci L; Frustaci AM; Gaidano G; Vitolo U; Morra E
    Leuk Lymphoma; 2015; 56(9):2637-42. PubMed ID: 25651423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis.
    Chan WL; Chong VCL; Wee IJY; Poon LM; Chan EHL; Lee J; Chee YL; Jeyasekharan AD; Chng WJ; Samuel M; de Mel S
    Blood Cancer J; 2023 Sep; 13(1):140. PubMed ID: 37679351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.
    Saito A; Isoda A; Kojima M; Yokohama A; Tsukune Y; Sasaki M; Ito S; Ohtsu A; Koike M; Murayama K; Moriya K; Tamura H; Matsumoto M; Nakahashi H; Tanosaki S; Sakura T; Kawamura T; Miyanaga T; Nakamura N; Murakami H; Handa H; Tsukamoto N
    Int J Hematol; 2017 Nov; 106(5):681-690. PubMed ID: 28687991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.